The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015

作     者：Xiaoling Chen Kewei Wang 

作者机构：Department of Molecular and Cellular Pharmacology State Key Laboratory of Natural and Biomimetic Drugs Peking University School of Pharmaceutical Sciences Department of Pharmacology Qingdao University School of Pharmacy 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2016年第6卷第6期

页      面：522-530页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

主　　题：Thrombosis Neuroprotective agent Ischemic stroke Traditional Chinese medicine Non-NMDA mechanism Ion channel 

摘      要：Stroke is a brain damage caused by a loss of blood supply to a portion of the brain, which requires prompt and effective treatment. The current pharmacotherapy for ischemic stroke primarily relies on thrombolysis using recombinant tissue plasminogen activators(rt-PAs) to breakdown blood clots. Neuroprotective agents that inhibit excitatory neurotransmitters are also used to treat ischemic stroke but have failed to translate into clinical benefits. This poses a major challenge in biomedical research to understand what causes the progressive brain cell death after stroke and how to develop an effective pharmacotherapy for stroke. This brief review analyzes the fate of about 430 potentially useful stroke medications over the period 1995–2015and describes in detail those that successfully reached the market. Hopefully, the information from this analysis will shed light on how future stroke research can improve stroke drug discovery.